Shopping Cart 0
Cart Subtotal
USD 0

Aeterna Zentaris Inc (AEZS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company's lead product, macimorelin, a ghrelin receptor agonist and orally-active small molecule that stimulates the secretion of growth hormone intended for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna Zentaris has licensed macimorelin to Strongbridge Biopharma plc, to develop, manufacture, register and commercialize in the US and Canada. Some of the other pipeline products of the company include Zoptrex. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.

Aeterna Zentaris Inc (AEZS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Aeterna Zentaris Enters into Agreement with EMD Serono 14

Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15

Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16

Licensing Agreements 17

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17

Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18

Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19

Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20

Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23

Equity Offering 24

Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24

Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25

Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26

Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28

Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For USD 50 Million 30

Aeterna Zentaris Completes Public Offering Of Units For USD 13.2 Million 31

AEterna Zentaris Completes Public Offering Of Units For USD 15 Million 32

AEterna Zentaris Completes Private Placement Of Units For USD 7.8 Million 34

AEterna Zentaris Announces Public Offering Of Shares For USD 4.6 Million 35

Aeterna Zentaris Completes Public Offering Of Units For USD 17 Million 36

Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For USD 2 Million 37

Aeterna Zentaris Inc-Key Competitors 38

Aeterna Zentaris Inc-Key Employees 39

Aeterna Zentaris Inc-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

Nov 06, 2018: Aeterna Zentaris reports third quarter 2018 financial and operating results 41

Aug 09, 2018: Aeterna Zentaris reports second quarter 2018 financial and operating results 42

May 07, 2018: Aeterna Zentaris Reports First Quarter 2018 Financial and Operating Results 43

Mar 28, 2018: Aeterna Zentaris Announces Fourth Quarter And Full-Year 2017 Financial Results 45

Nov 08, 2017: Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results 48

Aug 10, 2017: Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results 50

May 08, 2017: Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results 53

Mar 15, 2017: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results 55

Corporate Communications 57

Sep 25, 2018: Aeterna Zentaris names Leslie Auld as Chief Financial Officer 57

Mar 05, 2018: Aeterna Zentaris Names James Clavijo As Chief Financial Officer 58

Dec 08, 2017: Aeterna Zentaris Announces Departure of Interim Chief Financial Officer 59

Sep 25, 2017: Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer 60

Sep 01, 2017: Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer 61

Legal and Regulatory 62

Dec 22, 2017: Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore 62

Dec 21, 2017: David Dodd and Philip Theodore respond to claim by Aeterna Zentaris 63

Product News 64

12/20/2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency 64

03/05/2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit 65

Product Approvals 66

Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency 66

Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date 67

Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults 68

Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 69

Mar 07, 2017: Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen 70

Clinical Trials 71

May 01, 2017: Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex Did Not Achieve its Primary Endpoint 71

Apr 28, 2017: Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex 72

Mar 02, 2017: Aeterna Zentaris Announces Presentation Regarding Macrilen at 99th Annual Meeting of the Endocrine Society 73

Feb 14, 2017: Aeterna Zentaris Announces Zoptrex Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium 74

Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen 75

Jan 30, 2017: Aeterna Zentaris Announces Completion of Zoptrex Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017 77

Jan 04, 2017: Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen 78

Other Significant Developments 79

May 08, 2018: Aeterna Zentaris Announces Results of Annual and Special Shareholders' Meeting 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeterna Zentaris Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Aeterna Zentaris Enters into Agreement with EMD Serono 14

Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15

Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17

Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18

Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19

Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20

Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23

Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24

Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25

Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26

Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28

Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For USD 50 Million 30

Aeterna Zentaris Completes Public Offering Of Units For USD 13.2 Million 31

AEterna Zentaris Completes Public Offering Of Units For USD 15 Million 32

AEterna Zentaris Completes Private Placement Of Units For USD 7.8 Million 34

AEterna Zentaris Announces Public Offering Of Shares For USD 4.6 Million 35

Aeterna Zentaris Completes Public Offering Of Units For USD 17 Million 36

Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For USD 2 Million 37

Aeterna Zentaris Inc, Key Competitors 38

Aeterna Zentaris Inc, Key Employees 39

Aeterna Zentaris Inc, Subsidiaries 40

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aeterna Zentaris Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aeterna Zentaris Inc (Aeterna Zentaris) is a specialty biopharmaceutical company that focuses on the development and commercialization of novel pharmaceutical therapies for the treatment of endocrine disorders. The company's lead product, macimorelin, a ghrelin receptor agonist and orally-active small molecule that stimulates the secretion of growth hormone intended for the diagnosis of adult growth hormone deficiency (AGHD). Aeterna Zentaris has licensed macimorelin to Strongbridge Biopharma plc, to develop, manufacture, register and commercialize in the US and Canada. Some of the other pipeline products of the company include Zoptrex. Aeterna Zentaris is headquartered in Summerville, South Carolina, the US.

Aeterna Zentaris Inc (AEZS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deal Details 14

Partnerships 14

Aeterna Zentaris Enters into Agreement with EMD Serono 14

Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15

Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16

Licensing Agreements 17

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17

Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18

Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19

Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20

Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23

Equity Offering 24

Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24

Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25

Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26

Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28

Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For USD 50 Million 30

Aeterna Zentaris Completes Public Offering Of Units For USD 13.2 Million 31

AEterna Zentaris Completes Public Offering Of Units For USD 15 Million 32

AEterna Zentaris Completes Private Placement Of Units For USD 7.8 Million 34

AEterna Zentaris Announces Public Offering Of Shares For USD 4.6 Million 35

Aeterna Zentaris Completes Public Offering Of Units For USD 17 Million 36

Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For USD 2 Million 37

Aeterna Zentaris Inc-Key Competitors 38

Aeterna Zentaris Inc-Key Employees 39

Aeterna Zentaris Inc-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 41

Financial Announcements 41

Nov 06, 2018: Aeterna Zentaris reports third quarter 2018 financial and operating results 41

Aug 09, 2018: Aeterna Zentaris reports second quarter 2018 financial and operating results 42

May 07, 2018: Aeterna Zentaris Reports First Quarter 2018 Financial and Operating Results 43

Mar 28, 2018: Aeterna Zentaris Announces Fourth Quarter And Full-Year 2017 Financial Results 45

Nov 08, 2017: Aeterna Zentaris Reports Third Quarter 2017 Financial and Operating Results 48

Aug 10, 2017: Aeterna Zentaris Reports Second Quarter 2017 Financial and Operating Results 50

May 08, 2017: Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results 53

Mar 15, 2017: Aeterna Zentaris Reports Fourth Quarter and Full-Year 2016 Financial and Operating Results 55

Corporate Communications 57

Sep 25, 2018: Aeterna Zentaris names Leslie Auld as Chief Financial Officer 57

Mar 05, 2018: Aeterna Zentaris Names James Clavijo As Chief Financial Officer 58

Dec 08, 2017: Aeterna Zentaris Announces Departure of Interim Chief Financial Officer 59

Sep 25, 2017: Aeterna Zentaris Announces Appointment of Interim Chief Financial Officer 60

Sep 01, 2017: Aeterna Zentaris Announces Departure of Vice President, Finance & Chief Accounting Officer 61

Legal and Regulatory 62

Dec 22, 2017: Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore 62

Dec 21, 2017: David Dodd and Philip Theodore respond to claim by Aeterna Zentaris 63

Product News 64

12/20/2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency 64

03/05/2018: Aeterna Zentaris Provides Update on Previously Disclosed Class Action Lawsuit 65

Product Approvals 66

Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency 66

Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date 67

Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults 68

Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017 69

Mar 07, 2017: Aeterna Zentaris Announces EMA Pediatric Committee Agreement on the Pediatric Investigation Plan for Macrilen 70

Clinical Trials 71

May 01, 2017: Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex Did Not Achieve its Primary Endpoint 71

Apr 28, 2017: Aeterna Zentaris to Announce Top-Line Results of the ZoptEC Phase 3 Clinical Study of Zoptrex 72

Mar 02, 2017: Aeterna Zentaris Announces Presentation Regarding Macrilen at 99th Annual Meeting of the Endocrine Society 73

Feb 14, 2017: Aeterna Zentaris Announces Zoptrex Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium 74

Feb 13, 2017: Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen 75

Jan 30, 2017: Aeterna Zentaris Announces Completion of Zoptrex Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017 77

Jan 04, 2017: Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen 78

Other Significant Developments 79

May 08, 2018: Aeterna Zentaris Announces Results of Annual and Special Shareholders' Meeting 79

Appendix 80

Methodology 80

About GlobalData 80

Contact Us 80

Disclaimer 80


List Of Figure

List of Figures

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Aeterna Zentaris Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Aeterna Zentaris Inc, Medical Devices Deals, 2012 to YTD 2018 11

Aeterna Zentaris Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Aeterna Zentaris Enters into Agreement with EMD Serono 14

Aeterna Zentaris Enters into Co-Promotion Agreement with Ascend Therapeutics for EstroGel and Macrilen 15

Aeterna Zentaris Enters Into Co-Development Agreement With Ergomed Clinical Research For AEZS-108 16

Strongbridge Biopharma Enters into Licensing Agreement with Aeterna Zentaris 17

Aeterna Zentaris Enters into Licensing Agreement with Specialised Therapeutics Asia 18

Rafa Labs Enters into Licensing Agreement with Aeterna Zentaris 19

Orient EuroPharma Enters into Licensing Agreement with Aeterna Zentaris 20

Aeterna Zentaris Enters into Option Agreement to License AEZS-120 Product 21

Aeterna Zentaris Enters into Licensing Agreement with Sinopharm A-Think for Zoptarelin Doxorubicin 22

Aeterna Zentaris Enters Into Licensing Agreement With Merck For Cetrotide 23

Aeterna Zentaris Plans to Raise up to USD50 Million in Public Offering of Shares 24

Aeterna Zentaris Raises USD7.6 Million in Private Placement of Units 25

Aeterna Zentaris Raises USD16.7 Million in Public Offering of Shares and Warrants 26

Aeterna Zentaris Raises USD37 Million in Public Offering of Shares and Warrants 28

Aeterna Zentaris Files Registration Statement For Public Offering Of Shares For USD 50 Million 30

Aeterna Zentaris Completes Public Offering Of Units For USD 13.2 Million 31

AEterna Zentaris Completes Public Offering Of Units For USD 15 Million 32

AEterna Zentaris Completes Private Placement Of Units For USD 7.8 Million 34

AEterna Zentaris Announces Public Offering Of Shares For USD 4.6 Million 35

Aeterna Zentaris Completes Public Offering Of Units For USD 17 Million 36

Aeterna Zentaris Completes Second Tranche Of Public Offering Of Common Stock For USD 2 Million 37

Aeterna Zentaris Inc, Key Competitors 38

Aeterna Zentaris Inc, Key Employees 39

Aeterna Zentaris Inc, Subsidiaries 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aeterna Zentaris Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.